Home : November 2012 : November 01, 2012 News : Alethia Biotherapeutics Closes a $4.7 Million Financing to Advance its Bone Antiresorptive Program

Alethia Biotherapeutics Closes a $4.7 Million Financing to Advance its Bone Antiresorptive Program

November 01, 2012

MONTREAL, QUEBEC--(Marketwire - Nov. 1, 2012) - Alethia Biotherapeutics Inc., a privately held biotechnology company focusing on the development of therapeutic monoclonal antibodies announced today that it has closed a new financing. Alethia will use the proceeds to fund primarily its lead program. The financing included participation of current major investors comprising AgeChem Venture Fund, BDC Venture Capital and GO Capital in addition to a long-term partner and shareholder of the company, Cellscript of Wisconsin.

http://www.marketwire.com/mw/release.do?id=1720630&sourceType=3
Other Stories